|
Daily Medical Update
Prostatitis
Tuesday, July 07, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Sexual medicine reviews (2026) - Meta-Analysis
Key Findings
- Across 9 RCTs, ESWT improved erectile function versus control (SMD 0.80, 95% CI 0.31-1.28).
- ESWT reduced NIH-CPSI total scores versus control (SMD -1.14, 95% CI -1.73 to -0.55), with transient hematuria/hematospermia reported in 4 cases in 1 trial and no device-related adverse events in 6 of 7 trials.
📋 Practice Implication: ESWT can be considered for selected men with CP/CPPS plus erectile dysfunction when a nonpharmacologic option is preferred, but counseling should emphasize that efficacy certainty remains low.
|
The French journal of urology (2025) - Practice Guideline
Key Findings
- Alpha-blockers given for 2-3 days improved trial-without-catheter success rates versus no alpha-blocker, with no single agent showing superiority.
- Suprapubic catheterization improved comfort and reduced colonization versus urethral drainage, while clean intermittent self-catheterization improved quality of life in appropriate patients.
📋 Practice Implication: When prostatitis symptoms coexist with retention, management should distinguish true inflammatory pain from BPH-driven obstruction and use short-course alpha-blockade plus the least morbid drainage strategy.
|
The French journal of urology (2025) - Practice Guideline
Key Findings
- Prostatic artery embolization produced inferior outcomes versus TURP and showed better efficacy when prostate volume exceeded 80 cm3.
- Ejaculation-preserving surgery improved sexual function versus standard procedures in sexually active men, while aquablation and minimally invasive simple prostatectomy were supported as alternatives in selected anatomy.
📋 Practice Implication: For men whose chronic pelvic or voiding complaints are ultimately obstruction-driven rather than prostatitic, referral decisions should align procedure choice with prostate size, desired sexual function preservation, and tolerance for lower efficacy.
|
The French journal of urology (2025) - Practice Guideline
Key Findings
- Alpha-blockers were recommended as first-line treatment for moderate to severe LUTS, while 5-alpha-reductase inhibitors improved outcomes in prostates above 40 mL but required sustained long-term use.
- Tadalafil, alone or combined with alpha-blockers, improved moderate to severe LUTS when erectile dysfunction coexisted, and combination alpha-blocker/5-ARI therapy was indicated when prostate volume exceeded 40 mL.
📋 Practice Implication: In patients labeled with prostatitis who mainly have chronic urinary symptoms, guideline-directed medical therapy for LUTS/BPH should be reassessed before repeating empiric anti-inflammatory or antibiotic treatment.
|
World journal of urology (2026) - Systematic Review
Key Findings
- Ejaculation-sparing techniques markedly increased preservation of antegrade ejaculation versus conventional surgery (OR 15.11, 95% CI 8.96-25.46, p < 0.0001).
- Urinary symptom scores improved similarly early, favored ejaculation-sparing surgery at mid-term follow-up, and complication rates were similar between groups.
📋 Practice Implication: If surgery is needed after chronic pelvic pain workup reveals concomitant BPH, ejaculation-sparing endoscopic options merit discussion for sexually active patients because functional preservation does not appear to trade off against mid-term urinary relief.
|
|
💡
Summary
Recent higher-significance prostate literature was dominated by adjacent LUTS/BPH and procedural evidence, with only one directly prostatitis-focused meta-analysis in the validated set. For clinicians managing prostatitis-like presentations, the most actionable signal was modest low-certainty support for extracorporeal shock wave therapy in CP/CPPS with erectile dysfunction, while contemporaneous guideline and surgical evidence mainly informs differentiation from obstructive and post-treatment prostate conditions that can mimic or compound symptoms.
|
|